Merck presents new Pharmacokinetic data on ISENTRESS® (raltegravir) at 14th European AIDS conference
Company confirms development program for investigational once daily (QD) dosing…
16 October 2013 | By Merck
Company confirms development program for investigational once daily (QD) dosing regimen of ISENTRESS...